#United States #New York #Securities Fraud #Rosen Law Firm #Picard Medical

Investors of Picard Medical, Inc. Have a Unique Opportunity to Participate in Securities Fraud Class Action

Understanding the Opportunity

Recent developments in the case against Picard Medical, Inc. (NYSE American: PMI) have created a pivotal moment for investors who purchased securities in the company between September 2, 2025, and October 31, 2025. The Rosen Law Firm, a global leader in investor rights, has announced a significant deadline of April 13, 2026, for potential class action participants to step forward as lead plaintiffs in a lawsuit aimed at recovering losses related to alleged securities fraud.

These investors are now presented with a pathway to seek compensation without incurring any out-of-pocket expenses through a contingency fee arrangement. This means that if the lawsuit is successful, the firm will take a percentage of the recovery instead of charging upfront fees.

The Class Action Mechanism

To participate in the lawsuit, interested parties can visit the Rosen Law Firm's website here for further details or directly contact Phillip Kim, Esq. at 866-767-3653. Acting as the lead plaintiff comes with responsibilities, including directing the litigation process on behalf of other class members.

It's important to note that no class has been certified yet; hence, to be officially represented, individuals must retain counsel or opt to remain as absent class members without participating in court proceedings. However, the opportunity to recover any future compensation is not solely tied to being a lead plaintiff.

Details of the Allegations

The lawsuit alleges that during the specified class period, executives at Picard Medical made several materially false statements and failed to disclose critical negative information regarding the company’s operations and financial health. Notable accusations highlight that:
1. Fraudulent Promotions: Picard was allegedly involved in deceptive stock promotion tactics that included misinformation spread through social media platforms and the impersonation of financial professionals.
2. Insider Trading: Insiders reportedly used offshore or nominee accounts to facilitate the coordinated sell-off of shares amid a manipulated rise in stock prices.
3. Misleading Disclosures: The firm’s public communications omitted vital information regarding artificial trading activity and false rumors that propelled the stock price.
4. Consequential Misrepresentation: As a result of these misleading statements, the market was misled about the viability and prospects of Picard Medical, leading to inflated stock values based on unsubstantiated claims.

Why Choose Rosen Law Firm?

Rosen Law Firm emphasizes the importance of selecting experienced and qualified counsel for such matters. The firm has established a stellar track record for resolving securities class action cases, notably claiming the largest settlement ever against a Chinese company. Their reputation for success is underscored by multiple annual records, including being ranked first for the number of securities class action settlements since 2013 and recovering hundreds of millions for investors in recent years.

Experience and Recognition

The firm is led by Laurence Rosen, a key figure in the plaintiffs’ bar recognized for his accomplishments. Many attorneys from Rosen Law Firm are lauded in prestigious lists such as Lawdragon and Super Lawyers, reflecting their prowess in class action litigation.

Closing Remarks

For Picard Medical’s investors, acting swiftly could prove advantageous given the urgency of the approaching deadline. Whether engaging as lead plaintiff or merely seeking more information, those impacted by the alleged fraud should weigh their options carefully and consider legal representation that has a proven history in securities law. Keeping abreast of ongoing updates can be facilitated by following Rosen Law Firm on their social media channels including LinkedIn and Twitter.

This unique opportunity not only presents a chance for potential restitution but also emphasizes the importance of holding companies accountable for their actions to protect investor rights.